Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity

Volumn 3, Issue , 2010, Pages 43-48

  Via, Michael A ^a   Chandra, Himani ^b   Araki, Takako ^a   Potenza, Matthew V ^c   Skamagas, Maria ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Diabetes and Endocrinology   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bromocriptine; Diabetes; Dopamine agonists; Glycemic control

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CYCLOSET; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADD ON THERAPY; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOPAMINERGIC ACTIVITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TARGETING; ENERGY METABOLISM; FATIGUE; FATTY ACID BLOOD LEVEL; FIBROSIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPOTENSION; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC REGULATION; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PLEURAL FIBROSIS; PREVALENCE; PSYCHOSIS; RETROPERITONEAL FIBROSIS; REVIEW; SYNCOPE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEAKNESS; WEIGHT REDUCTION;

EID: 77953441285     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s9575     Document Type: Review

References (39)

1. Johnson WD, Kroon JJ, Greenway FL, Bouchard C, Ryan D, Katzmarzyk PT. Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001-2006. Arch Pediatr Adolesc Med. 2009;163:371-377.
2. Ryan JG. Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. Gend Med. 2009;6 Suppl 1:86-108.
3. ADA. 2008 Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31 Suppl 1:S12-S54.
4. Nathan DM. Finding new treatments for diabetes-how many, how fast... how good? N Engl J Med. 2007;356:437-440.
5. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
7. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
8. Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G. Drug insight: cabergoline and bromocriptine in the treatment of hyper- prolactinemia in men and women. Nat Clin Pract Endocrinol Metab. 2006;2:200-210.
9. Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999;8:1683-1707.
10. Scranton R, Cincotta, A, Gaziano, JM. The effect of timed Cycloset (a quick-release formulation of bromocriptine mesylate) on cardio- vascular events in patients with type 2 diabetes [abstract]. Diabetes. 2008;57:A95.
11. Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A. A ran- domized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes ther- apy and either Cycloset or placebo. BMC Endocr Disord. 2007;7:3.
12. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065-1078.
13. Sandoval D, Cota D, Seeley RJ. The integrative role of CNS fuel- sensing mechanisms in energy balance and glucose regulation. Annu Rev Physiol. 2008;70:513-535.
14. Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsy- chotic medication. Int J Clin Pract. 2007;61:1356-1370.
15. Cincotta AH, MacEachern TA, Meier AH. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol. 1993;264:E285-E293.
16. Cincotta AH, Meier AH. Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bro- mocriptine treatment. Life Sci. 1989;45:2247-2254.
17. Cincotta AH, Meier AH, Southern LL. Bromocriptine alters hormone rhythms and lipid metabolism in swine. Ann Nutr Metab. 1989;33: 305-314.
18. Southern LL, Cincotta AH, Meier AH, Bidner TD, Watkins KL. Bromocriptine-induced reduction of body fat in pigs. J Anim Sci. 1990;68:931-936.
19. Cincotta AH, Schiller BC, Meier AH. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism. 1991;40:639-644.
20. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667-670.
21. Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154-1161.
22. Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res. 2004;62:55-59.
23. Kamath V, Jones CN, Yip JC, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care. 1997;20:1697-1701.
24. Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine adminis- tration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia. 1992;48:248-253.
25. Wasada T, Kawahara R, Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care. 2000;23:1039-1040.
26. Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001;24:247-253.
27. Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol. 2005;513:225-228.
28. http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=1020. Accessed Dec 10, 2009.
29. Scranton RE EM, Gaziano JM, Cincotta A. Cycloset (bromocriptine mesylate accelerated absorbing) therapy improves glycemic control in type 2 diabetes (T2D) subjects failing thiazolidinedione (TZD) therapy [abstract]. American Diabetes Association 69th Annual Meeting; June 8, 2009:Abstract 481-P.
30. van Hilten JJ, Ramaker CC, Stowe R, Ives NJ. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database Syst Rev. 2007; CD002258.
31. Weil C. The safety of bromocriptine in long-term use: a review of the literature. Curr Med Res Opin. 1986;10:25-51.
32. Wiggins J, Skinner C. Bromocriptine induced pleuropulmonary fibrosis. Thorax. 1986;41:328-330.
33. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004;19:656-662.
34. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:39-46.
35. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002;10:334-336.
36. Daly JM, Hartz AJ, Xu Y, et al. An assessment of attitudes, behaviors, and outcomes of patients with type 2 diabetes. J Am Board Fam Med. 2009;22:280-290.
37. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008;71:474-480.
38. Sahay BK, Sahay RK. Hypertension in diabetes. J Indian Med Assoc. 2003;101:12, 14-15, 44.
39. Clausius N, Born C, Grunze H. The relevance of dopamine agonists in the treatment of depression. Neuropsychiatr. 2009;23:15-25.